Olema Pharmaceuticals, Inc. Common Stock
OLMA US68062P1066
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -80% | -74% | 431% | -58% | 6% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Harmon Cyrus O |
8.33 USD |
10,000 Sold |
83,300 USD |
16/09/2025 | 18/09/2025 |
| Harmon Cyrus O |
8.32 USD |
3,086 Sold |
25,676 USD |
16/09/2025 | 18/09/2025 |
| Harmon Cyrus O |
8.08 USD |
1,914 Sold |
15,465 USD |
16/09/2025 | 16/09/2025 |
| Harmon Cyrus O |
8.04 USD |
10,000 Sold |
80,400 USD |
16/09/2025 | 16/09/2025 |
| Graham G. Walmsley O |
6.75 USD |
700,761 Sold |
4,730,137 USD |
13/12/2024 | 17/12/2024 |
| Graham G. Walmsley O |
6.75 USD |
700,761 Sold |
4,730,137 USD |
13/12/2024 | 17/12/2024 |
| Zojwalla Naseem CMO |
8.66 USD |
14,202 Sold |
122,989 USD |
09/12/2024 | 11/12/2024 |
| Zojwalla Naseem CMO |
9.39 USD |
320 Sold |
3,005 USD |
09/12/2024 | 11/12/2024 |
| Bohen Sean CEO |
8.66 USD |
55,907 Sold |
484,155 USD |
09/12/2024 | 11/12/2024 |
| Kovacs Shane William Charles CFO |
8.66 USD |
17,950 Sold |
155,447 USD |
09/12/2024 | 11/12/2024 |